Cartesian Therapeutics (RNAC) announced positive initial data from its ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus, or SLE. The company reported a 100% LLDAS response rate and a disease remission, or DORIS, response in two out of three patients who reached the month 3 follow-up. Descartes-08 was observed to have a favorable safety profile supporting outpatient administration. Cartesian also announced the expansion of clinical development for Descartes-08 into myositis and now plans to pause further development in SLE to prioritize opportunities in myasthenia gravis and myositis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Reports Promising Phase 2 Trial Results
- Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year
- Cartesian Therapeutics Announces Leadership Changes
- Cartesian Therapeutics announces employment inducement grant
- Cartesian Therapeutics appoints Brunn as Chairman of Board